0.00Open109.50Pre Close0 Volume1 Open Interest150.00Strike Price0.00Turnover91.50%IV3.09%PremiumDec 20, 2024Expiry Date101.72Intrinsic Value100Multiplier25DDays to Expiry7.78Extrinsic Value100Contract SizeAmericanOptions Type0.9894Delta0.0005Gamma2.46Leverage Ratio-0.0500Theta0.1011Rho2.43Eff Leverage0.0186Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet